➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
McKinsey

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

AZOPT Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Azopt patents expire, and when can generic versions of Azopt launch?

Azopt is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in AZOPT is brinzolamide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the brinzolamide profile page.

US Patents and Regulatory Information for AZOPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AZOPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998   Start Trial   Start Trial
Novartis AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998   Start Trial   Start Trial
Novartis AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for AZOPT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0527801 CA 2009 00014 Denmark   Start Trial
0527801 C300098 Netherlands   Start Trial PRODUC NAME: BRINZOLAMIDUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; NATL. REGISTRATION NO/DATE: EU/1/00/129/01-02 20000309; FIRST REGISTRATION: CH IKS 55236 19991217
0527801 SPC/GB03/004 United Kingdom   Start Trial PRODUCT NAME: BRINZOLAMIDE; REGISTERED: CH IKS 55236 19991217; UK EU/1/00/129/01 20000309; UK EU/1/00/129/02 20000309
0527801 91555 Luxembourg   Start Trial 91555, EXPIRES: 20160403
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.